CoChat

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Open access
Ferrannini, Giulia, Gerstein, Hertzel, Colhoun, Helen Martina, Dagenais, Gilles R, Diaz, Rafael, Dyal, Leanne, Lakshmanan, Mark, Mellbin, Linda, Probstfield, Jeffrey, Riddle, Matthew Casey, Shaw, Jonathan Edward, Avezum, Alvaro, Basile, Jan Neil, Cushman, William C, Jansky, Petr, Keltai, Mátyás, Lanas, Fernando, Leiter, Lawrence Alan, Lopez-Jaramillo, Patricio, Pais, Prem, Pīrāgs, Valdis, Pogosova, Nana, Raubenheimer, Peter Johann, Sheu, Wayne Huey-Herng, Rydén, Lars · 2021 · European Heart Journal
Cited by 28

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Objective: Recent European Guidelines for Diabetes, Prediabetes and Cardiovascular Diseases introduced a shift in managing patients with type 2 diabetes at high risk for or established cardiovascular (CV) disease by recommending GLP-1 receptor agonists and SGLT-2 inhibitors as initial glucose-lowering therapy. This is questioned since outcome trials of these drug classes had metformin as background therapy. In this post hoc analysis, the effect of dulaglutide on CV events was investigated according to the baseline metformin therapy by means of a subgroup analysis of the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. Research design and methods: Patients in REWIND (n = 9901; women: 46.3%; mean age: 66.2 years) had type 2 diabetes and either a previous CV event (31%) or high CV risk (69%). They were randomized (1:1) to sc. dulaglutide (1.5 mg/weekly) or placebo in addition to standard of care. The primary outcome was the first of a composite of nonfatal myocardial infarction, nonfatal stroke, and death from cardiovascular or unknown causes. Key secondary outcomes included a microvascular composite endpoint, all-cause death, and heart failure. The effect of dulaglutide in patients with and without baseline metformin was evaluated by a Cox regression hazard model with baseline metformin, dulaglutide assignment, and their interaction as independent variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated by a Cox regression model with adjustments for factors differing at baseline between people with vs. without metformin, identified using the backward selection. Results: Compared to patients with metformin at baseline (n = 8037; 81%), those without metformin (n = 1864; 19%) were older and slightly less obese and had higher proportions of women, prior CV events, heart failure, and renal disease. The primary outcome occurred in 976 (12%) participants with baseline metformin and in 281 (15%) without. There was no significant difference in the effect of dulaglutide on the primary outcome in patients with vs. without metformin at baseline [HR 0.92 (CI 0.81–1.05) vs. 0.78 (CI 0.61–0.99); interaction P = 0.18]. Findings for key secondary outcomes were similar in patients with and without baseline metformin. Conclusion: This analysis suggests that the cardioprotective effect of dulaglutide is unaffected by the baseline use of metformin therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa777

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 28

Metadata

Authors
Ferrannini, G., Gerstein, H., Colhoun, H. M., Dagenais, G. R., Diaz, R., Dyal, L., Lakshmanan, M., Mellbin, L., Probstfield, J., Riddle, M. C., Shaw, J. E., Avezum, A., Basile, J. N., Cushman, W. C., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., Pais, P., Pīrāgs, V., Pogosova, N., Raubenheimer, P. J., Sheu, W. H.-H., & Rydén, L.
Venue
European Heart Journal
Published
2020-11-16
Volume
42
Issue
26
Pages
2565-2573
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3100058299
Cited by
28
References
15
FWCI
3.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa777
The paper
Ferrannini, G., Gerstein, H., Colhoun, H. M., Dagenais, G. R., Diaz, R., Dyal, L., Lakshmanan, M., Mellbin, L., Probstfield, J., Riddle, M. C., Shaw, J. E., Avezum, A., Basile, J. N., Cushman, W. C., Jansky, P., Keltai, M., Lanas, F., Leiter, L. A., Lopez-Jaramillo, P., . . . Rydén, L. (2021). Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa777

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.